DOSAGE FORM DESIGN FOR IMPROVEMENT OF BIOAVAILABILITY OF LEVODOPA .6. FORMULATION OF EFFERVESCENT ENTERIC-COATED TABLETS

被引：11

作者：

NISHIMURA, K ^{[1
]}

SASAHARA, K ^{[1
]}

ARAI, M ^{[1
]}

NITANAI, T ^{[1
]}

IKEGAMI, Y ^{[1
]}

MORIOKA, T ^{[1
]}

NAKAJIMA, E ^{[1
]}

机构：

[1] SANKYO CO LTD,PROD DEV LABS,1 CHOME 2-58,TOKYO 140,JAPAN

来源：

JOURNAL OF PHARMACEUTICAL SCIENCES | 1984年 / 73卷 / 07期

关键词：

D O I：

10.1002/jps.2600730720

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

引用

页码：942 / 946

页数：5

共 7 条

[1] MODIFICATION OF PARKINSONISM - CHRONIC TREATMENT WITH L-DOPA [J].

COTZIAS, GC ;

PAPAVASI.PS ;

GELLENE, R .

NEW ENGLAND JOURNAL OF MEDICINE, 1969, 280 (07) :337-&

[2]

IKEDA M, 1971, 91ST ANN M PHARM SOC

[3]

MATSUMOTO K, 1972, JPN J GASTROENTEROLO, V69, P783

[4]

SAKAMOTO K, 1967, HDB EXPT SURGERY MED, P258

[5] DOSAGE FORM DESIGN FOR IMPROVEMENT OF BIOAVAILABILITY OF LEVODOPA .5. ABSORPTION AND METABOLISM OF LEVODOPA IN INTESTINAL SEGMENTS OF DOGS [J].

SASAHARA, K ;

NITANAI, T ;

HABARA, T ;

MORIOKA, T ;

NAKAJIMA, E .

JOURNAL OF PHARMACEUTICAL SCIENCES, 1981, 70 (10) :1157-1160

[6] DOSAGE FORM DESIGN FOR IMPROVEMENT OF BIOAVAILABILITY OF LEVODOPA-IV - POSSIBLE CAUSES OF LOW BIOAVAILABILITY OF ORAL LEVODOPA IN DOGS [J].

SASAHARA, K ;

NITANAI, T ;

HABARA, T ;

KOJIMA, T ;

KAWAHARA, Y ;

MORIOKA, T ;

NAKAJIMA, E .

JOURNAL OF PHARMACEUTICAL SCIENCES, 1981, 70 (07) :730-733

[7]

WATANABE K, 1976, 96TH ANN M PHARM SOC

← 1 →